Učitavanje...

The effect of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes

Patients with type 2 diabetes have a significantly increased risk of cardiovascular disease (CVD) compared to the general population—with CVD accounting for two out of every three deaths in patients with diabetes. In 2008, the FDA suggested that CVD risk should be evaluated for any new antidiabetic...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Clin Cardiol
Glavni autori: Dey, Amit K., Groenendyk, Jacob, Mehta, Nehal N., Gourgari, Evgenia
Format: Artigo
Jezik:Inglês
Izdano: Wiley Periodicals, Inc. 2019
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6414247/
https://ncbi.nlm.nih.gov/pubmed/30635924
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.23152
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!